Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 4/20 | 0.48 |
| ▸ | HTR2A | P28223 | 3/20 | 0.46 |
| ▸ | HTR2B | P41595 | 3/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14701443 | 0.89 | GPR119 (0.58) | TACR1GPR119SMYD3MAPTDPP4 | |
| SCHEMBL24168673 | 0.80 | MGLL (0.50) | TACR1MEN1KMT2ASLC6A4DRD3 | |
| SCHEMBL14701462 | 0.80 | TACR1 (0.49) | TACR1MEN1KMT2ARORCEPHX1 | |
| SCHEMBL30334881 | 0.80 | MGLL (0.50) | TACR1MEN1KMT2ASLC6A4DRD3 | |
| SCHEMBL30334922 | 0.79 | TEAD1 (0.60) | TACR1SCN9AMEN1KMT2A | |
| SCHEMBL26215470 | 0.79 | TEAD1 (0.60) | TACR1SCN9AMEN1KMT2A | |
| SCHEMBL3038735 | 0.78 | RORC (0.42) | TACR1GPR119GHSRRORCMAPT | |
| SCHEMBL3031564 | 0.77 | CACNA1B (0.52) | RORC | |
| SCHEMBL21896201 | 0.77 | MGLL (0.61) | TACR1MEN1KMT2ASLC6A4DRD3 | |
| SCHEMBL31168855 | 0.77 | MGLL (0.61) | TACR1MEN1KMT2ASLC6A4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130040932-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040932-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | TRPV1, TRPA1, CACNA1D | TACR1 889/4885HTR2A 282/4885HTR2B 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.